拉米夫定治疗HBV-DNA阳性失代偿期肝硬化疗效观察

目的探讨拉米夫定治疗HBV-DNA阳性失代偿期肝硬化的疗效。方法将60例HBV-DNA阳性的失代偿期肝硬化患者,随机分为治疗组、对照组,每组30例,在综合治疗的基础上加用拉米夫定100mg/d,服用1年。对照组采用常规综合治疗。结果治疗组肝功能恢复及症状体征总有效率86.67%,HBV-DNA转阴率86.7%,HBeAg转阴率56.7%,与对照组相比差别有统计学意义(P<0.05)。结论拉米夫定治疗HBV-DNA阳性的失代偿期肝硬化可提高HBV-DNA及HBeAg转阴率,改善肝功能失代偿的症状,使病情稳定,提高患者生活质量。

The curative effects of Lamividine in treatment of the active liver cirrhosis of HBV-DNA positive

Objective To observe the effects of Lamividine in treating the active liver cirrhosis of positive HBV-DNA. Methods 60 cases with the active liver cirrhosis of positive HBV-DNA were divided into two groups. The treatment group (30 cases) were treated with Lamividine, the control group (30 cases) were treated with general method.Results The effective rate in treatment group of clinical symptoms was 86.67%. The negative rate of HBV-DNA was 86.7%, the negative rate of HBeAg was 56.7%. There was a significant difference between the treatment group and the control group (P<0.05).Conclusion The negative rates of HBV-DNA and HBeAg increase after the active liver cirrhosis of HBV-DNA positive treated with Lamividine. The clinical symptoms and the quality of life is improved.